RXRX stock forecast, quote, news & analysis
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company... Show more
Recursion Pharmaceuticals (RXRX) Stock Analysis: AI-Driven Drug Discovery Consolidates After a Sharp Rally
Key Takeaways
- RXRX traded near $4.03, little changed from roughly $4.12 a month earlier (about a 2% decline), signaling consolidation after a sharp late-summer advance.
- Over the trailing quarter, shares climbed from around $3.18 in early August, a gain of roughly 27%, as investor interest in AI-enabled drug discovery reaccelerated.
- Recursion Pharmaceuticals is a clinical-stage biotech that applies artificial intelligence and machine learning across target discovery, chemistry, and preclinical development.
- Long-term investors focus on pipeline progression, platform collaborations, and cash runway rather than short-term price swings.
- Biotech equities of this profile remain sensitive to clinical data, sector rotation, and shifts in interest-rate expectations.
- For additional context, explore RXRX Price Targets, Earnings, and Forecast pages.
- Discover how automated strategies approach this name by exploring Trending AI Robots.
Current Market Snapshot
Recursion Pharmaceuticals has settled into a period of consolidation. After a pronounced upward move in mid-September, the stock pulled back and traded in a range through October before recovering to roughly $4.03. That compares with a closing level near $4.12 about 30 days earlier, leaving the one-month change modestly negative even as the broader quarterly trend remains firmly higher.
The stock's behavior reflects the volatile, sentiment-driven nature of clinical-stage biotech names tied to the artificial intelligence theme. Investors are weighing enthusiasm for AI-powered drug discovery against the fundamental reality that early-stage platforms generate limited near-term revenue and depend heavily on research milestones and partnership economics.
Recursion Pharmaceuticals (RXRX) Business Overview and Competitive Position
Recursion Pharmaceuticals is a clinical-stage biotechnology company headquartered in Salt Lake City, Utah, that aims to industrialize drug discovery. Its core asset is the Recursion Operating System, a platform that combines automated wet-laboratory experiments, high-dimensional biological imaging, and machine-learning models to generate and mine biological data at scale.
The company applies this platform across oncology, neuroscience, rare diseases, and infectious disease, seeking to identify novel targets and advance small-molecule programs through preclinical and clinical development. Recursion has built strategic relationships with technology and pharmaceutical partners, including a long-standing collaboration with NVIDIA around AI and accelerated computing, as well as alliances with major pharmaceutical companies. The completed combination with Exscientia expanded its chemistry and design capabilities and reinforced its position among AI-first drug-discovery companies.
Recent Developments Driving RXRX
Over the last 30 days, RXRX price action has been shaped more by market dynamics than by a single isolated catalyst. The stock experienced elevated volatility in mid-October, including several sessions with above-average trading volume, before stabilizing toward month-end. This pattern is consistent with profit-taking and repositioning following the sharp gains recorded in late September, when shares advanced from the low-$3 range toward the low-$4 range over a handful of sessions.
Sector-level factors continue to influence sentiment. AI-linked biotechnology equities remain correlated with the broader technology trade, and small- and mid-cap biotech names are particularly sensitive to changes in interest-rate expectations and risk appetite. For Recursion specifically, investors continue to monitor the integration of the Exscientia platform, the progression of its clinical pipeline, and the durability of its technology partnerships, which together define the company's longer-term narrative.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies from a platform that offers hundreds of AI trading bots covering thousands of tickers. Only the top-performing and most relevant bots appear in this section, giving traders a focused view of strategies that are currently attracting attention. These bots vary widely in approach, holding timeframe, and performance metrics, so the page can serve as a useful starting point for exploring how algorithmic systems are positioned across the market. Traders interested in data-driven, automated approaches may find value in reviewing the available strategies.
2026 Outlook and What Investors Should Watch
Looking ahead, the key drivers for Recursion Pharmaceuticals center on execution rather than short-term price momentum. Investors are likely to monitor clinical data readouts and pipeline advancement, as tangible proof of the platform's ability to produce viable drug candidates remains central to the investment case. Updates on partnership economics, licensing deals, and the continued integration of Exscientia will also shape sentiment.
On the macro side, the path of interest rates and the broader availability of capital for biotech innovation will influence valuations across the sector. Competitive developments in AI-driven drug discovery, including advances from peers and technology partners, represent an additional factor to track. As with all early-stage biotech investments, the balance sheet and cash runway remain critical considerations for the company's ability to fund research through meaningful milestones.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RXRX's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Oscillator for RXRX moved out of overbought territory on October 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 25 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 57 cases where RXRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for RXRX turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 38 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
RXRX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on RXRX as a result. In 83 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
RXRX moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for RXRX moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +14.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in 207 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 108 of 131 cases where RXRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.274) is normal, around the industry mean (2.904). P/E Ratio (-3.880) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology